CORESEARCH collabora con diverse strutture a livello nazionale e internazionale per la valutazione dell’impatto economico di specifiche terapie o di strategie assistenziali complesse.
In una situazione di limitatezza delle risorse disponibili e di attenzione alla sostenibilità del sistema, sempre più spesso è infatti richiesto di documentare il rapporto fra efficacia e costi degli interventi sanitari messi in atto o il peso economico generato da specifiche patologie, dai loro trattamenti e dalle loro complicanze.
Le attività svolte includono studi di cost of illness e di cost-effectiveness, eseguiti utilizzando, grandi database amministrativi, database di dati clinici o indagini ad hoc.

 

Pubblicazioni:

  1. Giorda CB, Rossi MC, Ozzello O, Gentile S, Aglialoro A, Chiambretti A, Baccetti F, Gentile FM, Romeo F, Lucisano G, Nicolucci A; HYPOS-1 Study Group of AMD. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study. Nutr Metab Cardiovasc Dis 2017; 27: 209-216.
  2. Nicolucci A, Buseghin G, De Portu S. Short-term cost analysis of complications related to glycated hemoglobin in patients with type 1 diabetes in the Italian setting. Acta Diabetol. 2015;52:677-85 .
  3. Darbà J, Kaskens L, Detournay B, Kern W, Nicolucci A, Orozco-Beltrán D, Ramírez de Arellano A. Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study. Clinicoecon Outcomes Res. 2015;7:163-71.
  4. Giorda CB, Nicolucci A, Pellegrini F, Kristiansen CK, Hunt B, Valentine WJ, Vespasiani G. Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis. Diabet Med. 2014;31:615-23.
  5. Nicolucci A, Rossi MC. Il diabete: una sfida per i sistemi sanitari. Italian Health Policy Brief. Speciale 2014. ALTIS Ed.
  6. Schuetz CA, Alperin P, Guda S, van Herick A, Cariou B, Eddy D, Gumprecht J, Nicolucci A, Schwarz P, Wareham NJ, Witte DR, Smith U. A standardized vascular disease health check in europe: a cost-effectiveness analysis. PLoS One. 2013;8:e66454.
  7. Franciosi M, Lucisano G, Amoretti R, Capani F, Bruttomesso D, Di Bartolo P, Girelli A, Leonetti F, Morviducci L, Vitacolonna E, Nicolucci A. Costs of treatment and complications of adult type 1 diabetes. Nutr Metab Cardiovasc Dis. 2013;23:606-11
  8. De Berardis G, D’Ettorre A, Graziano G, Lucisano G, Pellegrini F, Cammarota S, Citarella A, Germinario CA, Lepore V, Menditto E, Nicolosi A, Vitullo F, Nicolucci A; DADA (Diabetes Administrative Data Analysis) Study Group. The burden of hospitalization related to diabetes mellitus: a population-based study. Nutr Metab Cardiovasc Dis. 2012;22:605-12.
  9. Leal I, Sammon C, Masclee GMC, Scotti L, De Berardis G, Bezemer I, Gil M, Martin E, McGrogan A, Schmedt N, Seeger JD, Trifirò G, Pecchioli S, Varas-Lorenzo C, Smits MM, Rijnbeek P, Sturkenboom MCJM, Romio S. Trends of Use of Non-Insulin Blood Glucose Lowering Drugs in Europe and USA. Poster presented at the 31st International Conference on Pharmacoepidemiology (ICPE) & Therapeutic Risk Management. August 2015. [abstract] Pharmacoepidemiol Drug Saf. 2015; 24(S1):106.
  10. Leal I, Sammon C, Masclee GMC, Corrao G, De Berardis G, Bezemer I, Gil M, Martin E, McGrogan A, Schmedt N, Seeger JD, Trifirò G, Pecchioli S, Varas-Lorenzo C, Smits MM, Rijnbeek P, Sturkenboom MCJM, Romio S. Patterns of Use of Incretin-Based Therapies in Europe and USA. Poster presented at the 31st International Conference on Pharmacoepidemiology (ICPE) & Therapeutic Risk Management. August 2015. [abstract] Pharmacoepidemiol Drug Saf. 2015; 24(S1):106.
  11. Leal I, Masclee GMC, Scotti L, De Berardis G, Bezemer I, Gil M, Martin E, Sammon C, Schmedt N, Seeger JD, Trifirò G, Pecchioli S, Varas-Lorenzo C, Smits MM, Rijnbeek P, Sturkenboom MCJM, Romio S. Identification of Type 2 Diabetes Mellitus in Different Electronic Databases Within the SAFEGUARD Project. Oral presentation at the 30th International Conference on Pharmacoepidemiology (ICPE) & Therapeutic Risk Management. October 2014; [abstract] Pharmacoepidemiol Drug Saf. Oct 2014; 23(S1): 193-194.